Healthcare Industry News: Bard
News Release - September 21, 2009
Brennen Medical Announces Sale of XenMatrix(R)ST. PAUL, Minn., Sept. 21 -- (Healthcare Sales & Marketing Network) -- Brennen Medical, LLC, a leader in biomaterials technology, announces the sale of its XenMatrix(R) device to Davol Inc., a subsidiary of C.R. Bard, Inc. The agreement provides Davol with the worldwide rights and related assets of the hernia products business of Brennen Medical, LLC. This acquisition includes technology for a non crosslinked xenograft device for use in soft tissue repair including hernia and abdominal wall reconstruction.
XenMatrix employs a proprietary technology that maintains an acellular structurally intact, non crosslinked porcine dermal matrix for enhanced biocompatibility in host tissue. This dermal matrix supports revascularization, remodeling and regeneration for abdominal wall and hernia repairs. Recently published data in the American Journal of Surgery from the Brigham and Women's Hospital studied the use of XenMatrix in complex abdominal wall defects and reported a 93% success rate with over 16 months follow-up.
"We are extremely pleased with the successful clinical outcomes of XenMatrix. Now with the acquisition by C.R. Bard, this product will reach a far greater number of patients worldwide, who will truly benefit from this device," said Phillip Lawin, PhD, President of Brennen Medical.
About Brennen Medical, LLC
Brennen Medical is a world leader providing biologic porcine xenograft for use in plastic reconstructive, general surgery, burn, trauma, wound, urogynecological and orthopedic soft tissue repair procedures. Demonstrated to be effective, surgeons have used Brennen's proprietary porcine technologies for over 40 years. Mediskin(R) and EZ Derm(R), XenMatrix and DermMatrix(R) provide the basis for innovation and quality to guide the Company's initiatives for a growing biosurgical market. Based in St. Paul, MN and privately held, the products are sold through a direct sales force and through partnerships with major medical device companies. In addition to porcine, Brennen also markets a line of products containing oat beta glucan, a natural complex carbohydrate successfully used to manage burn and chronic wounds.
XenMatrix and DermMatrix are trademarks and/or registered trademarks of C. R. Bard, Inc. or an affiliate.
Mediskin and EZ Derm are registered trademarks of Brennen Medical, LLC.
Source: Brennen Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.